Atossa Therapeutics Secures Patent for Z-Endoxifen, Enhancing Breast Cancer Treatment Strategy

Atossa Therapeutics Strengthens Intellectual Property for Z-Endoxifen

Atossa Therapeutics, Inc. makes notable advancements in its intellectual property strategy for Z-endoxifen, a critical component in its breast cancer treatment portfolio. On October 13, 2025, the company announces the issuance of an essential patent in Israel (No. 304863), titled "Methods for Making and Using Endoxifen." This patent, granted on July 2, 2025, bolsters the protection of Z-endoxifen formulations, which contain a minimum of 90% by weight of the compound, alongside strict limits on impurities. The patent specifies important release characteristics and pharmacokinetic performance targets, such as plasma exposure levels and steady-state concentrations, which are vital for ensuring the drug's efficacy and safety.

The newly issued patent also details manufacturing methods that enhance the production of Z-endoxifen through innovative techniques, including stepwise crystallization and solvent control. This aligns with Atossa’s quality-by-design approach, which emphasizes meticulous planning and execution in drug development to enhance therapeutic outcomes. By focusing on these advanced manufacturing processes, Atossa aims to guarantee the highest quality of Z-endoxifen for patients, thereby addressing significant unmet needs in breast cancer therapy. The company’s commitment to innovation is evident, as it seeks to establish a robust presence in the biopharmaceutical market with a focus on effective treatments for this pervasive disease.

Steven Quay, M.D., Ph.D., Atossa's Chairman and CEO, highlights the importance of strong patent protections in supporting the company’s strategic vision for Z-endoxifen. Such protections not only facilitate the delivery of high-quality products to patients but also serve to create long-term shareholder value. The issuance of the Israeli patent, coupled with a Certificate of Patent Renewal from the Israel Patent Office, underscores the comprehensive nature of Atossa's intellectual property strategy, ensuring that the company maintains a stronghold over its innovative therapies in major jurisdictions. This proactive approach reflects Atossa's dedication to tackling the challenges presented by breast cancer, while also reinforcing its position as a leader in the biopharmaceutical industry.

In parallel with its patent advancements, Atossa Therapeutics continues to prioritize disciplined capital allocation and strategic investments in research and development. This focus ensures that the company can effectively navigate the complexities of drug development while remaining committed to its mission of improving patient outcomes in breast cancer care. The recent patent issuance serves as a testament to Atossa's ongoing efforts to innovate and expand its therapeutic offerings in a competitive market.